SIGIRR hFc Chimera, Human
| $300.00 | |
| Z05815-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| $300.00 | |
| Z05815-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 39.29 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 50-70 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
The purity of SIGIRR hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »
SIGIRR hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | TIR8, also known as single Ig IL-1-related receptor, is a member of the IL-1 receptor/Toll-like receptor (TLR) superfamily, which acts as an intracellular decoy for components of the signaling pathway. Structurally, it is characterized by a single extracellular Ig domain, an intracellular TIR domain and 95-aa cytoplasmic tail. Recently, TIR8 was shown to inhibit NF-?B activation by members of the IL-1/TLR family. The inhibitory activity of TIR8 was associated with trapping of TRAF6 and IRAK1. |
| Synonyms | TIR8; Single Ig IL-1-related receptor; IL-1R8 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.